Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a biopharmaceutical company dedicated to creating innovative medicines that significantly improve the lives of patients. Founded in 1998, Ironwood specializes in gastrointestinal (GI) therapeutics and has a strong focus on developing and commercializing treatments for chronic conditions of the GI tract.
The company's flagship product is a medicine designed for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This medicine, discovered and developed by Ironwood, is now fully commercialized and widely used to alleviate symptoms in patients, improving their quality of life.
Ironwood's research pipeline is robust, with multiple investigational medicines targeting both the upper and lower GI tract. The company leverages its expertise in gastrointestinal disorders and pharmacologic expertise in guanylate cyclases to develop new therapies that address unmet medical needs.
Beyond its core product, Ironwood is actively exploring new opportunities and expanding its portfolio through collaborative licenses, commercial agreements, and strategic acquisitions. These efforts aim to enhance the company's research, development, manufacturing, and marketing capabilities, thereby driving growth and innovation.
Recent achievements for Ironwood include the advancement of several clinical trials, promising data from ongoing research studies, and strategic partnerships aimed at enhancing product development and market reach. Financially, Ironwood continues to build value, achieving milestones that attract continued support from shareholders.
Ironwood Pharmaceuticals remains committed to its mission of making a difference for patients through the development of groundbreaking therapies. The company’s strong pipeline, dedicated team, and strategic initiatives position it as a leading player in the field of gastrointestinal therapeutics.
Ironwood Pharmaceuticals reported a strong Q3 2022, with a 10% year-over-year increase in LINZESS prescription demand, reaching over 1 million prescriptions in a quarter for the first time. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA for LINZESS in pediatric patients by the end of 2022. Financial highlights include a GAAP net income of $50 million and adjusted EBITDA of $69 million. Ironwood maintains its guidance for 2022, expecting total revenue between $420 million and $430 million.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its third quarter 2022 investor update conference call on November 3, 2022, at 8:30 a.m. ET. Participants can join by calling (888) 330-2384 for U.S. and Canada or (240) 789-2701 internationally, using conference ID 4671230. A replay will be available starting the same day at 11:30 a.m. ET until November 17, 2022. The archived webcast will be accessible on Ironwood’s website for 14 days post-call. Ironwood focuses on advancing gastroenterological treatments, especially for IBS-C and CIC.
Ironwood Pharmaceuticals announced positive topline results from a Phase III trial of linaclotide in pediatric patients aged 6-17 with functional constipation (FC). The study met its primary and secondary endpoints, demonstrating significant improvements in spontaneous bowel movements and stool consistency compared to placebo. Linaclotide was generally well-tolerated, with diarrhea being the most common side effect. There are currently no FDA approved pediatric treatments for FC, affecting 4-6 million children in the U.S. Ironwood and partner AbbVie may file for a supplemental New Drug Application (sNDA).
Ironwood Pharmaceuticals (Nasdaq: IRWD) will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference scheduled for September 8, 2022, at 8:00 a.m. ET in Everett, MA. A live webcast will be available on the company's website, with a replay accessible for 14 days post-conference. Ironwood is renowned for its gastrointestinal healthcare focus, particularly with LINZESS®, a leading treatment for IBS-C and CIC. Founded in 1998 and headquartered in Boston, Massachusetts, Ironwood aims to redefine GI care.
Ironwood Pharmaceuticals reported its Q2 2022 results, showcasing a 9% year-over-year growth in LINZESS prescription demand. Despite this, total revenues decreased to $97.2 million from $104.0 million in Q2 2021, with GAAP net income dropping significantly to $37 million from $391 million. The company completed its share repurchase program and repaid $120.7 million in convertible notes. Ironwood reiterated its guidance for 2022, projecting low single-digit U.S. LINZESS net sales growth and total revenue between $420 million and $430 million.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announces an investor update conference call on August 4, 2022, at 8:30 a.m. ET. Participants can join by calling (888) 330-2384 (U.S.) or (240) 789-2701 (international) with conference ID 4671230. The call will be recorded and available for replay starting at 11:30 a.m. ET the same day until August 18, 2022. Ironwood specializes in gastrointestinal healthcare, particularly with its LINZESS® treatment for IBS-C and CIC. More details can be found on their website.
Ironwood Pharmaceuticals (Nasdaq: IRWD) presented new findings at the 2022 Digestive Disease Week that suggest IW-3300 could manage abdominal pain in patients with disorders of gut-brain interaction. Current Phase I trials aim to explore this compound's potential for visceral pain conditions, including interstitial cystitis and endometriosis. The company also shared insights on the efficacy of linaclotide in treating IBS-C and functional constipation in pediatric patients, aiming to address the unmet needs in gastrointestinal diseases.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will showcase eight studies, including two oral presentations, at the Digestive Disease Week 2022 conference in San Diego from May 21 to May 24. One key study focuses on IW-3300's effect on chronic pelvic pain, while another analyzes linaclotide's impact on abdominal symptoms in IBS-C patients. CEO Tom McCourt will receive the ASGE President’s Award for his contributions to gastrointestinal endoscopy, highlighting Ironwood's ongoing commitment to GI health advancements.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported Q1 2022 results, highlighting an 11% year-over-year growth in LINZESS® (linaclotide) prescription demand. The U.S. net sales of LINZESS reached $232 million, marking an 8% increase year-over-year. Total revenue for the quarter was $98 million, with collaboration revenue from LINZESS at $94 million. The company achieved a GAAP net income of $39 million and ended the quarter with $593 million in cash. Ironwood remains focused on pipeline development and ongoing clinical trials for new GI treatments.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its first quarter 2022 investor update conference call on May 5, 2022, at 8:30 a.m. Eastern Time. Participants can join via phone or access a webcast from Ironwood's website. A replay will be available from 11:30 a.m. ET on the same day until May 19, 2022. Ironwood is known for its development of LINZESS®, a leading treatment for gastrointestinal diseases, aiming to improve care standards for patients with IBS-C and CIC.
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
What does Ironwood Pharmaceuticals specialize in?
What is Ironwood's flagship product?
When was Ironwood Pharmaceuticals founded?
What are some of Ironwood's recent achievements?
How does Ironwood plan to expand its research and development capabilities?
What areas does Ironwood's research pipeline target?
What other conditions, besides IBS-C and CIC, is Ironwood working on?
How does Ironwood build value for its shareholders?
Where is Ironwood Pharmaceuticals listed?
What is the company's mission?
